Detalhe da pesquisa
1.
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
J Infect Dis
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38682569
2.
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
J Infect Dis
; 225(9): 1521-1532, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319249
3.
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Clin Infect Dis
; 75(1): 107-117, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606595
4.
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Lancet
; 395(10234): 1434-1443, 2020 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32197107
5.
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Lancet
; 395(10234): 1423-1433, 2020 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32197105
6.
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Glob Health
; 12(2): e257-e270, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245116
7.
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study.
Expert Rev Vaccines
; 21(5): 685-692, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220869
8.
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Hum Vaccin Immunother
; 18(5): 2044255, 2022 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344464
9.
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Lancet Infect Dis
; 18(2): 162-170, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29122463
10.
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
PLoS Negl Trop Dis
; 12(6): e0006340, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29874228
11.
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Lancet Infect Dis
; 17(6): 615-625, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28365225